Search

everythinglearnresearchcommunity

for

Search:↓

The patch behind the ear is likely traction alopecia caused by glasses. No specific treatments like Minoxidil, finasteride, or RU58841 were mentioned.

Managing estradiol levels while using finasteride. Treatments discussed include Minoxidil, finasteride, and RU58841.

A user reports significant hair regrowth after 2 months using Minoxidil, Finasteride, oiling, derma rolling, and taking multivitamins, omega 3, and vitamin D. Some users discuss the frequency of derma rolling, with varying practices ranging from once every two weeks to four times a week.

The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.

User is 1.5 months into using oral minoxidil and finasteride for hair regrowth, along with dermarolling. They report good progress and seek advice on whether new hairs will thicken.

A user was prescribed ketoconazole shampoo by their dermatologist for early-stage hair loss, but is unsure if this is the right treatment. Most commenters suggest seeking a second opinion or starting finasteride treatment immediately, while a few caution about potential side effects.

A user stopped using minoxidil after 10-12 years due to severe side effects like fluctuating blood pressure and chest pain, resulting in significant hair loss. Other users shared similar experiences, emphasizing health over hair and suggesting alternatives like finasteride, nanoxidil, and rosemary oil.

A 47-year-old male experienced hair regrowth after 4 months of using topical minoxidil and derma stamping, with additional use of keto shampoo. He noticed improvements, especially at the back and front of his head, despite irregular derma stamping sessions.

Hair loss improvement in 4 months using finasteride and minoxidil. Users express surprise and interest in trying minoxidil.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A user discusses starting nandrolone replacement therapy to stop hair loss and improve hair health, noting its benefits over finasteride. They report halted hair loss, improved skin, increased muscle, and a calm mood after three weeks.

Minoxidil and caffeine may interact, affecting hair growth results. Users shared mixed experiences, with some noticing improvements without caffeine and others still seeing results despite coffee consumption.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.